Sector News

Amazon, finding drugs aren't so easy, nixes one sales plan: CNBC

April 17, 2018
Life sciences

Amazon’s potential leap into pharmaceuticals has weighed on drug distributors and pharmacies for months, but those companies are getting relief from news that the online retail giant has put at least one of its plans on ice.

CNBC reported that Amazon Business—a unit that sells bulk products to companies—hasn’t been able to convince hospitals to get on board with its plan. One reason: The company doesn’t have a proper cold-chain logistics network, which is crucial to distributing many drugs, according to CNBC’s sources. Amazon has now backed away from the effort, the publication reported.

This doesn’t mean drug suppliers should rest easy, however. The company is pressing ahead with other healthcare projects, though it’s unknown whether they involve pharmaceutical sales. Among those are programs underway with Alexa and at the “1492” team, according to CNBC.

In a note to clients Monday, Wells Fargo analyst David Maris wrote that while the “report may suggest Amazon Business has shelved its drug distribution plan for the time being, we strongly suggest investors continue to pay close attention to Amazon’s actions in this arena.”

“Amazon has a history of disrupting even previously entrenched industries and business methods and its entry does not usually spell increased profit margins for its competitors,” he wrote in the note.

Still, shares of drug distribution and pharmacy companies, such as CVS Health, McKesson, Cardinal Health, jumped on the news.

Meanwhile, the pharma distribution business has been undergoing significant change even without an Amazon move into the sector. UnitedHealth and Aetna recently pledged to provide drug rebates to certain members, addressing a longstanding complaint by pharma that patients aren’t benefiting from tough pricing negotiations.

And last month, leading independent pharmacy benefit manager Express Scripts agreed to sell itself to Cigna in a $52 billion deal. With that acquisition, the top three PBMs by market share will be tied to insurers. At the time, Paula Wade, a principal analyst at Decision Resources Group, told FiercePharma the buyout was “part of a realignment of the whole industry in response to the frustration” over drug pricing. CVS and Aetna are also merging in a $69 billion deal, tying CVS’ PBM Caremark with the insurer.

Apart from those moves, Amazon itself made a headline-catching announcement in January with its decision to partner with JP Morgan and Berkshire Hathaway to try and curb growing healthcare costs, though details about the approach remain unknown.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).